Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging
NEJM 378:708-718, Albers, G.W.,et al, 2018
Benefits of Emergency Departments Contribution to Stroke Prophylaxis in Atrial Fibrillation
Stroke 48:1344-1352, Coll-Vinent, B.,et al, 2017
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013
Long-Term Cognitive Function, Neuroimaging and Quality of Life in Primary CNS Lymphoma
Neurol 81:84-92, Doolittle, N.,et al, 2013
Current Concepts and Management of Glioblastoma
Ann Neurol 70:9-21, Preusser, M.,et al, 2011
The Cost-Effectiveness of Telestroke in the Treatment of Acute Ischemic Stroke
Neurol 77:1590-1598, Nelson, R.E.,et al, 2011
Long-Term Survival with Favorable Cognitive Outcome After Chemotherapy in Primary Central Nervous System Lymphoma
Ann Neurol 67:182-189, Juergens,A.,et al, 2010
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab
Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007
Self-Monitoring of Oral Anticoagulation: A Systematic Review and Meta-Analysis
Lancet 367:404-411,412, Heneghan,C.,et al, 2006
High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis
Arch Neurol 63:1388-1393, Gladstone,D.E.,et al, 2006
Cognitive Status and Quality of Life After Treatment for Primary CNS Lymphoma
Neurol 62:544-547,532, Harder,H.,et al, 2004
Recent Developments in Bell's Palsy
BMJ 329:553-557, Holland,N.J. & Weiner,G.M., 2004
Surgical Decompression of Patients with Large Middle Cerebral Artery Infarcts is Effective
Stroke 34:2304-2305,2307, Schwab,S.&Hacke,W., 2003
Surgical Decopression of Patients With Large Middle Cerebral Artery Infarcts is Effective:Not Proven
Stroke 34:2305-2306,2307, Brown,M.M., 2003
Cost-Effectiveness of Tissue Plasminogen Activator for Acute Ischemic Stroke
Neurol 50:883-890, Fagan,S.C.,et al, 1998
HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Impact of Interferon Beta-1A On Neurologic Disability in Relapsing Multiple Sclerosis
Neurol 49:358-363, Rudick,R.A.,et al, 1997
Frequent & Frequently Overlooked:Trtm-Induced Endocrine Dysf in Adult Long-Term Survivors of Primary Brain Tumors
Neurol 49:498-506, Arlt,W.,et al, 1997
The Quality-of-Life Effects of Interferon Beta-1b in MS
Arch Neurol 54:1475-1480, Schwartz,C.E.,et al, 1997
Management of Patients Receiving Interferon Beta-1b for MS:Report of a Consensus Conf
Neurol 46:12-18, Lublin,F.D.,et al, 1996
Radiotherapy for Malignant Glioma
BMJ 313:1500-1501, Gregor,A.,et al, 1996
Cost-Effectiveness of Warfarin and Aspirin for Prophylaxis of Stroke in Patients with Nonvalvular Atrial Fibrillation
JAMA 274:1839-1845, Gage,B.F.,et al, 1995
Neurologic Manifestations of HIV Infection
Ann Int Med 121:769-785, Simpson,D.M.&Tagliati,M., 1994
An Aggressive Approach to Massive Middle Cerebral Artery Infarction
Arch Neurol 50:1293-1297, Kalia,K.K.&Yonas,H., 1993
Primary Central Nervous System Lymphoma
Ann Int Med 119:1093-1104, Fine,H.A.&Mayer,R.J., 1993
The Treamtent of Primary Malignant Brain Tumours
JNNP 54:101-103, 182-1831991., Whittle,I.R.&Gregor,A., 1991
Influence of Low-Intensity Warfarin Treatment of Patients'Perceptions of Quality of Life
Editorial, Arch Int Med 151:1921-1922, 1944-1949991., , 1991
Treatment of Right Hemispheric Cerebral Infarction by Hemicraniectomy
Stroke 21:874-881, Delashaw,J.B.,et al, 1990